领航心血管智能化精准介入 北芯生命即将登陆科创板

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has received approval for its initial public offering and is set to list on the Sci-Tech Innovation Board, focusing on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] Group 1: Company Overview - Beixin Life is a national high-tech enterprise specializing in the research, production, and sales of innovative medical devices for cardiovascular disease diagnosis and treatment [1] - The company is the first in China to have a product combination of intravascular functional FFR and imaging IVUS, establishing a high-performance and high-barrier system for active interventional medical devices [2] Group 2: Product Development and Innovation - As of September 30, 2025, Beixin Life has launched 11 products and has 6 products under research, covering five major categories including IVUS systems and FFR systems [2] - The core product, the IVUS system, is the first domestically developed 60MHz high-definition and high-speed IVUS product approved by the National Medical Products Administration, featuring high definition, speed, and intelligence [2] Group 3: Financial Performance - In the first half of 2025, sales revenue from FFR pressure microcatheters and IVUS catheters accounted for 82.16% of total sales, indicating the continued dominance of core products in the market [3] - Beixin Life achieved a revenue of 259 million yuan and a net profit of 45.51 million yuan in the first half of 2025, marking its first profitable period [3] Group 4: Intellectual Property and Recognition - As of June 30, 2025, Beixin Life holds 185 authorized patents domestically and internationally, including 86 invention patents and 14 PCT international patent applications [4] - The company has been recognized as a "National Specialized and New 'Little Giant' Enterprise" and has received various awards for its core products, highlighting its technological capabilities and market recognition [4] Group 5: Future Outlook - The upcoming IPO is expected to optimize the company's capital structure, reduce debt risk, and enhance its research and development capabilities [6] - Beixin Life aims to continue advancing its product development and expand the application range of existing products, solidifying its comprehensive platform for cardiovascular disease diagnosis and treatment [6]